Strategic Alliance Alchem Laboratories has formed a strategic alliance with Mark Cuban Cost Plus Drug Company to develop essential medicine therapeutics and improve supply chain resiliency, presenting a co-selling and co-development opportunity for expanded product offerings and joint go-to-market initiatives.

Manufacturing Capabilities As a CRO with cGMP manufacturing and custom organic synthesis, Alchem can be targeted for upfront development partnerships, scale-up of promising drug candidates, and outsourced manufacturing for late-stage clinical programs or commercial production.

Therapeutic Focus The launch of Partuza, a breast cancer drug in India, signals exposure to oncology indications. This creates potential sales opportunities in collaboration with partners seeking manufacturing, analytics, and global regulatory support for oncology therapeutics.

Growth Readiness With a revenue range of 10 to 25 million and a lean team, Alchem may benefit from enterprise-level CRO partnerships, strategic funding channels, and scalable manufacturing arrangements to drive capacity planning and long-term contracted services.

Analytical and Compliance Edge Alchem’s capabilities in analytical services alongside cGMP manufacturing position it as a valuable partner for pharmaceutical companies requiring integrated development-to-manufacturing solutions, enabling cross-sell into analytics, quality control, and regulatory readiness.